PDS Phase 2 Clinical Trial Update

RNS Number : 8524P

NetScientific PLC

21 October 2021

 

NetScientific plc

("NetScientific", the "Group" or the "Company")

PDS Phase 2 Clinical Trial Update

 

PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

London, UK - 21 October 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group,  announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), has announced the temporary suspension of recruitment in the National Cancer Institute (NCI)-led Phase 2 clinical trial (NCT04287868) evaluating PDS0101 (Versamune^®-HPV16) in combination with two investigational immune-modulating agents in advanced HPV cancers.

As indicated by PDS, the issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination. It is anticipated that this temporary suspension in recruitment for this clinical trial will be determined in a timely manner and is not expected to affect the overall timing of clinical data. Once resolved, the PDS0101 trial recruitment will resume immediately.

The trial is evaluating the novel combination in both checkpoint inhibitor naïve and refractory patients with advanced HPV-associated cancers that have progressed or returned after treatment. The vast majority of these cancers are caused by HPV16.

Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech said: "We know from the interim data that this combination has the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options. While the trial is experiencing a slight administrative delay, we are pleased to report that the PDS0101 trial recruitment has progressed well and it is anticipated that it will resume recruitment shortly. We believe, based on the previously reported results, that this treatment could significantly improve survival benefit for these patients, and we look forward to resumption of the trial in the near term."

Ilian Iliev, CEO of NetScientific, commented: "As indicated by PDS, it is anticipated that this temporary suspension in recruitment for this clinical trial will be resolved in a timely manner and is not expected to affect the overall timing of clinical data. The issue is not specific to the PDS0101 trial and is unrelated to any safety or efficacy concerns with the triple combination. We remain supportive of the PDS strategy and look forward to clinical data and the next milestones."

Full details of the announcement from PDS can be viewed here:

https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/569-iotechrovidespdateonationalancernstitutee20211021

For more information, please contact:

NetScientific	Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel	[phone]
Walbrook PR
Nick Rome/ Paul McManus/ Nicholas Johnson	07748 325 236, 07980 541 893 or 07884 664 686

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops, commercialises and realises shareholder value in life sciences/healthcare, sustainability and technology companies, which offer significant growth potential predominately in the UK and USA, as well as globally. 

With the acquisition of EMV Capital in August 2020, the Group doubled its portfolio from 8 to 17 companies, either through direct subsidiary, balance sheet investment or capital under advisory, varying from start-up private companies to publicly listed equities. 

NetScientific delivers shareholder returns through a proactive and hands-on management approach to their portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong transatlantic and growing international presence, providing attractive expansion prospects. 

NSCI can deploy a capital-light investment structure; utilising the power of the PLC Brand, and the NetScientific balance sheet to anchor future investments and achieve a multiplier effect by attracting 3rd party investment for the portfolio companies. 

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013 (website:  www.netscientific.net ).

 

END

 

 

RESMBBJTMTBTBIB